The gut microbiome influences immune checkpoint inhibitor (ICI) efficacy.
In this study, we explored the effects of combined levofloxacin (LVFX) and Clostridium butyricum MIYAIRI 588 (CBM588) on ICI outcomes using a CT26 tumor model in BALB/c mice.
When compared with the control, the LVFX+CBM588 combination enhanced anti-programmed cell death (PD)-1 therapy, with CD8
